EG 427 Announces Attendance at Conferences in H1 2024

February 13, 2024

EG 427 announces today it will present at several conferences in H1 2024 about the company’s latest results and corporate development.

  • BIO CEO & Investor Conference, New York, USA, Feb 26-27, 2024
    • Don Haut, Chief Business Officer, will give an in-person presentation on Feb 26 at 4pm ET.
  • BIO Europe Spring, Barcelona, Spain, March 18-20, 2024
    • Philippe Chambon, co-founder and CEO, will give an in-person presentation.
  • BioEquity Europe, San Sebastian, Spain, May 12-14, 2024
    • Philippe Chambon, co-founder and CEO, will give an in-person presentation.

Access the full press release in English and in French

< back

Recent posts

First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study
First gene therapy for prevalent pathologies in neurology receives FDA IND clearance - EG 427 initiating first-in-human clinical study

read more >

EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB
EG 427 Announces New Preclinical Results from Multiple Studies of EG110A in NDO and OAB

read more >

×

By clicking Consent, you accept the saving of all cookie data on your device. If you click Denied, only the data necessary for the website to function is saved. More information about cookies in the privacy policy.

settings Reject I agree
×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.